SCHEMBL26547607

SCHEMBL26547607

Cc1cc2c(Br)cncc2n(C)c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 2/20 0.38
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 2/20 0.37
GLA P06280 1/20 0.37
AAK1 Q2M2I8 2/20 0.36
GABRA5 P31644 1/20 0.35
NQO2 P16083 1/20 0.34
HSD17B10 Q99714 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
ATAD2 Q6PL18 1/20 0.33
THRB P10828 1/20 0.32
AURKA O14965 1/20 0.31
KDR P35968 1/20 0.31
AURKB Q96GD4 1/20 0.31
NPC1 O15118 1/20 0.31
MAPT P10636 1/20 0.31
XBP1 P17861 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23487171 0.79 HSD17B10 (0.37) HSD17B10ADORA3ADORA2A
SCHEMBL31426258 0.76 BRPF1 (0.40) BRPF1KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL26547742 0.76 BRPF1 (0.40) BRPF1KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL26547562 0.75 KDM4E (0.50) BRPF1KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL30480838 0.75 KDM4E (0.50) BRPF1KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL26547672 0.73 TTR (0.40) BRPF1KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL30480908 0.73 TTR (0.40) BRPF1KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL26547632 0.72 CYP19A1 (0.43) BRPF1KDM4EALDH1A1NQO2THRB
SCHEMBL27448899 0.71
SCHEMBL25489117 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 US disclosed
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 US disclosed
CN-116368128-A Heterocyclic compounds as CBP/EP300 bromodomain inhibitors 奥瑞基尼肿瘤有限公司 2023-06-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS EP300, HDAC1, BRD3 BRPF1 216/4885KDM4E 472/4885ALDH1A1 2743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.